| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | NYSE |
| Shares Outstanding | 392.44M |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: There’s No Way We’ll See More Railroad M&A
Jim Cramer says the antitrust environment out there will make it difficult for any railroad mergers to be approved by regulators.
Federal Reserve to Reassess Global Risks in Minutes on Wednesday
Investors are gearing up for another assessment of the global economy, as the Fed Prepares to release the minutes of its March meeting.
Can Allergan-Pfizer Survive Treasury's New Crackdown on Inversions?
The latest rules are seen likely to prompt a rethink of the $150 billion pharmaceuticals deal.
Jim Cramer: The Allergan-Pfizer Deal Is Absolutely Dead
Jim Cramer says the merger between Pfizer and Allergan isn't going anywhere, as lawmakers try to limit corporate inversions.
Jim Cramer: Valeant Needs a Government Monitor
TheStreet's Jim Cramer said Valeant Pharmaceuticals' (VRX) move to appoint billionaire investor Bill Ackman to the board of directors isn't enough and a government monitor is needed.
Emergency Medicine Of The Future Demonstrated At ACEP15
"InnovatED" to Feature Emergency Simulations and Next Generation Technology
Healthcare M&A Resilient Despite Economic Woes
Despite the financial hardships plaguing some economies, healthcare M&A is still on the rise and experts indicate there is no sign of it slowing.
Valeant Pharmaceuticals Buys Maker of Female Viagra, Sprout for $1B
Laval, Quebec-based Valeant Pharmaceuticals International Inc. (VRX) announced on Thursday that it would purchase privately owned Sprout Pharmaceuticals Inc. for $1 billion.
Today's Stocks Driving Success For The Drugs Industry
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Weekly Roundup
We put our large cash position to work this week, building our stakes in two portfolio names.
Jim Cramer -- Let's Face It, Allergan's Kythera Acquisition Is 'Brilliant'
The Botox maker now has complete 'facial domination,' Cramer says.
5 Stocks Larry Robbins Loves Even Though They're Not Health Care Stocks
Glenview Capital's Larry Robbins has hit the nail on the head with his health care picks in recent years, but they're not his only investments you should be watching.
Failed Greece Negotiations Hit Futures; Dollar Worries Persist
But investors are likely to be wary ahead of the Fed meeting.
Weekly Roundup
This week, we added to two portfolio holdings, took some profits off the table in others, and exited one position.
Jim Cramer's Top Takeaways: Actavis, Rite Aid, Receptos
Cramer is impressed by Rite Aid, even though it is expensive, and Receptos, which he says is the best early-stage biotech.
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
Cramer will be watching earnings from Sears, Lululemon and Cisco, among others, next week.
Weekly Roundup
We made few moves in the portfolio this week as mixed data produced volatile trading across asset classes.
Why Actavis Shares Are Underperforming
We have tremendous confidence in Actavis' ability to deliver.
Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum
- Actavis Commitment Extends to Fostering Collaborative Research Efforts, Gathering Unique Epidemiological Information and Generating Real-World Data to Demonstrate the Effects of Stewardship on Patient Outcomes -
Weekly Roundup
This week, we swapped new positions for old in the energy and health care sectors, as the market ended in the red.
Actavis Added to Citigroup's U.S. Focus List
Actavis' attractive near to medium-term organic growth profile is not reflected in current valuation levels.
3 Drugs Stocks Nudging The Industry Higher
TheStreet highlights 3 stocks pushing the drugs industry higher today.
FDA Approval of Viberzi Is Bullish for Actavis
The new drug complements the company's offer in the field.
Actavis Receives FDA Approval For VIBERZI (eluxadoline) For The Treatment Of Irritable Bowel Syndrome With Diarrhea (IBS-D) In Adults
-First in class treatment for IBS-D treats hallmark symptoms of IBS-D; abdominal pain and diarrhea
Infectious Disease Experts, Scientists And Clinicians Join Forces On SHARE ID™ To Accelerate The Battle Against Antibiotic-resistant Infections
- Initiative Supported by Actavis Aims to Help Advance Evidence-Based Treatment Practices Using Unique Data-Sharing Platform -
Weekly Roundup
We added two new positions to the portfolio this week as the S&P 500 moved slightly higher.